Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $23.1 million.

  • Macrogenics' Accumulated Expenses fell 631.8% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year decrease of 631.8%. This contributed to the annual value of $29.3 million for FY2024, which is 2101.98% up from last year.
  • Macrogenics' Accumulated Expenses amounted to $23.1 million in Q3 2025, which was down 631.8% from $21.3 million recorded in Q2 2025.
  • Macrogenics' 5-year Accumulated Expenses high stood at $41.9 million for Q3 2021, and its period low was $18.1 million during Q1 2024.
  • Moreover, its 5-year median value for Accumulated Expenses was $28.2 million (2023), whereas its average is $29.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 3561.8% in 2024, then surged by 5338.88% in 2025.
  • Macrogenics' Accumulated Expenses (Quarter) stood at $33.8 million in 2021, then fell by 14.09% to $29.0 million in 2022, then decreased by 16.41% to $24.2 million in 2023, then increased by 21.02% to $29.3 million in 2024, then decreased by 21.3% to $23.1 million in 2025.
  • Its last three reported values are $23.1 million in Q3 2025, $21.3 million for Q2 2025, and $27.8 million during Q1 2025.